Is Lyell Immunopharma Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Lyell Immunopharma Inc (LYEL) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Lyell Immunopharma Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Lyell Immunopharma Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Lyell Immunopharma Inc?

Muslim investors may consider investing in Lyell Immunopharma Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Lyell Immunopharma Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Lyell Immunopharma Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Lyell Immunopharma Inc updated?

The Shariah compliance status of Lyell Immunopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Lyell Immunopharma Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Lyell Immunopharma Inc?

You can check the latest Shariah compliance status of Lyell Immunopharma Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

LYEL Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 15, 2026

Report Source: 2026 1st Quarter Report

Lyell Immunopharma Inc. Stock Analysis LYEL

United States Health Care Small Cap Report: Q1, 2026

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 161 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Key Statistics of Lyell Immunopharma Inc (LYEL)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$17.43$18.73

Today's Open

$18.56

Volume

107.62K

P/E Ratio (TTM)

52 Week Range

$7.65$45.00

Market Cap

481.12M

Avg. Volume

66.39K

Dividend Yield

Financial Metrics & Statements of Lyell Immunopharma Inc (LYEL)

FAQ's for Lyell Immunopharma Inc (LYEL)

According to Musaffa’s Shariah screening methodology, Lyell Immunopharma Inc (LYEL) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.